Myocardial Injury After Noncardiac Surgery (MINS) in Lumbar Surgery Patients
Launched by ANKARA CITY HOSPITAL BILKENT · Jul 15, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how often heart injury happens after lumbar (lower back) surgery that is not related to the heart, and what factors might increase the risk of this happening. The researchers want to better understand if patients having planned lower back surgery experience any heart problems during or after the procedure, especially focusing on a condition called myocardial injury, which means damage to the heart muscle.
Adults aged 18 and older who are scheduled for elective lumbar stabilization surgery may be eligible to join the study. People with a recent heart attack (within the last 30 days), a history of heart surgery, or consistently high levels of a heart-related protein called troponin will not be able to participate. If you join the trial, the medical team will monitor your heart health closely before, during, and after your back surgery to check for any signs of heart injury. This study is not yet recruiting participants but aims to help improve care and outcomes for patients undergoing this type of surgery in the future.
Gender
ALL
Eligibility criteria
- • Inclusion criteria Age ≥18 years Elective lumbar stabilization surgery
- • Exclusion criteria History of cardiac surgery Recent acute MI (\<30 days) Chronic elevated troponin levels
About Ankara City Hospital Bilkent
Ankara City Hospital Bilkent is a leading healthcare institution in Turkey, dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals, the hospital fosters a collaborative environment for conducting rigorous scientific investigations. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the highest level of integrity, ultimately contributing to the development of new therapies and enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported